159992 创新药
已收盘 04-25 15:00:00
资讯
新帖
简况
中国生物制药(01177)：1类创新药“TQA3038 (siRNA)”完成I期临床研究
智通财经 · 49分钟前
中国生物制药(01177)：1类创新药“TQA3038 (siRNA)”完成I期临床研究
贝达药业：主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异
证券之星 · 52分钟前
贝达药业：主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异
4月25日常山药业涨停分析：化学原料药，创新药，医药概念热股
证券之星 · 15:28
4月25日常山药业涨停分析：化学原料药，创新药，医药概念热股
4月25日康弘药业涨停分析：眼科，合成生物，创新药概念热股
证券之星 · 15:28
4月25日康弘药业涨停分析：眼科，合成生物，创新药概念热股
恒瑞医药(600276)年报点评报告：业绩符合预期，创新药收入占比显著提升，全球化战略持续推进
国盛证券 · 11:18
恒瑞医药(600276)年报点评报告：业绩符合预期，创新药收入占比显著提升，全球化战略持续推进
港股异动 | 创新药概念股走高 科济药业-B(02171)涨超11% 创新药迎来全流程支持机制
智通财经 · 11:17
港股异动 | 创新药概念股走高 科济药业-B(02171)涨超11% 创新药迎来全流程支持机制
恒瑞医药(600276)：业绩企稳 创新药收入持续增长
海通证券 · 04-23 20:24
恒瑞医药(600276)：业绩企稳 创新药收入持续增长
腾讯出手，投了家创新药公司
猎云精选 · 04-23 20:10
腾讯出手，投了家创新药公司
复星医药董秘回复： 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官，复宏汉霖执行董事、董事会主席
证券之星 · 04-23 18:12
复星医药董秘回复： 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官，复宏汉霖执行董事、董事会主席
京新药业：作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升
证券之星 · 04-23 18:04
京新药业：作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升
恒瑞医药(600276)2023年年报及2024年一季报点评：创新药驱动业绩增长，领军创新药行业发展
光大证券 · 04-23 15:17
恒瑞医药(600276)2023年年报及2024年一季报点评：创新药驱动业绩增长，领军创新药行业发展
A股收评 | 创新药午后爆发 人形机器人走强
智通财经网 · 04-23 15:12
A股收评 | 创新药午后爆发 人形机器人走强
港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖
智通财经 · 04-23 13:55
港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖
创新药概念午后震荡回升 甘李药业涨停
市场资讯 · 04-23 13:24
创新药概念午后震荡回升 甘李药业涨停
联环药业钱振华：持续加大研发投入，加速推进创新药、高端仿制药等研发进度
地产k线 · 04-23 11:12
联环药业钱振华：持续加大研发投入，加速推进创新药、高端仿制药等研发进度
天士力获首创证券买入评级，业绩符合预期，中药创新药有望进入收获期
金融界 · 04-22 19:03
天士力获首创证券买入评级，业绩符合预期，中药创新药有望进入收获期
恒瑞医药(600276)2023年年报及2024年一季报点评：创新药快速增长，研发管线亮点纷呈
兴业证券 · 04-22
恒瑞医药(600276)2023年年报及2024年一季报点评：创新药快速增长，研发管线亮点纷呈
恒瑞医药(600276)年报点评：创新药驱动收入增长，2024年迎来产品上市高峰
国联证券 · 04-22
恒瑞医药(600276)年报点评：创新药驱动收入增长，2024年迎来产品上市高峰
中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点
阿斯达克财经 · 04-19
中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点
中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果
阿斯达克财经 · 04-11
中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.671,"timestamp":1714028613000,"preClose":0.663,"halted":0,"volume":280793877,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":0.008,"latestTime":"04-25 15:00:00","open":0.662,"high":0.679,"low":0.66,"amount":188000000,"amplitude":0.0287,"askPrice":0.672,"askSize":34138,"bidPrice":0.671,"bidSize":1110,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714095000000},"adr":0,"adjPreClose":0.663,"symbolType":"fund","openAndCloseTimeList":[[1714008600000,1714015800000],[1714021200000,1714028400000]],"highLimit":0.729,"lowLimit":0.597,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":-0.148258,"marketValue":0,"floatMarketCap":0,"changeRate":0.0121,"turnoverRate":0,"status":0,"discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992/wiki","defaultTab":"wiki","newsList":[{"id":"2430474785","title":"中国生物制药(01177)：1类创新药“TQA3038 (siRNA)”完成I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2430474785","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430474785?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:05","pubTimestamp":1714039536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的1类创新药“TQA3038 ”已于近日顺利完成I期临床研究。TQA3038采用具有自主知识产权的核酸序列，与目前临床进展最快的siRNA 相比，具有更强的体外及体内抗病毒活性。集团发起的“评价TQA3038在健康成年受试者中安全性、耐受性、药代动力学特征的随机、双盲、安慰剂对照的I期临床研究”已于近日顺利完成。集团将于近期启动TQA3038注射液在慢性乙型肝炎患者中的后续临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110081.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430725134","title":"贝达药业：主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异","url":"https://stock-news.laohu8.com/highlight/detail?id=2430725134","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430725134?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:02","pubTimestamp":1714039377,"startTime":"0","endTime":"0","summary":"主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异。根据港股招股书，贝达药业耗费大量现金用于投资房地产，在2018年-2020年初，贝达药业持有投资性房地产分别为5.24亿元、5.77亿元及0.36亿元。若归属期内公司业绩水平未达到业绩考核目标条件，会冲销前期已计提的相关股份支付费用。目前BPI-16350项目尚未开展一线适应症临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500038780.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430421337","title":"4月25日常山药业涨停分析：化学原料药，创新药，医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430421337","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430421337?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030125,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业涨停收盘，收盘价11.77元。该股于9点31分涨停，未打开涨停，截止收盘封单资金为1.57亿元，占其流通市值1.45%。4月25日的资金流向数据方面，主力资金净流入2.19亿元，占总成交额41.29%，游资资金净流出1.31亿元，占总成交额24.68%，散户资金净流出8800.39万元，占总成交额16.61%。近5日资金流向一览见下表：该股为化学原料药，创新药，医药概念热股，当日化学原料药概念上涨2.05%，创新药概念上涨1.85%，医药概念上涨1.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026171.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430636421","title":"4月25日康弘药业涨停分析：眼科，合成生物，创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430636421","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430636421?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030100,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业涨停收盘，收盘价20.13元。该股于9点42分涨停，5次打开涨停，截止收盘封单资金为3337.67万元，占其流通市值0.24%。4月25日的资金流向数据方面，主力资金净流入3968.23万元，占总成交额6.44%，游资资金净流出2841.33万元，占总成交额4.61%，散户资金净流出1126.9万元，占总成交额1.83%。近5日资金流向一览见下表：该股为眼科，合成生物，创新药概念热股，当日眼科概念上涨2.17%，合成生物概念上涨1.9%，创新药概念上涨1.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026139.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430445217","title":"恒瑞医药(600276)年报点评报告：业绩符合预期，创新药收入占比显著提升，全球化战略持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2430445217","media":"国盛证券","top":-1,"share":"https://www.laohu8.com/m/news/2430445217?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:18","pubTimestamp":1714015136,"startTime":"0","endTime":"0","summary":"恒瑞医药发布2023年年报。恒瑞医药发布2024年一季报。分产品类型看，2023年公司创新药收入106.37亿元，同比增长22.1%；占比营收46.61%，相比2022年创新药收入比例提升6.13pp。公司2023年研发投入合计61.50亿元，占比营收26.95%。随着创新药商业化梯队持续丰富，创新药销售收入占比将逐渐提升，拉动公司长期发展，海外布局则开辟更广阔空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511294887ad4faa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511294887ad4faa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443247","title":"港股异动 | 创新药概念股走高 科济药业-B(02171)涨超11% 创新药迎来全流程支持机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443247","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430443247?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:17","pubTimestamp":1714015021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股持续走高，截至发稿，科济药业-B(02171)涨10.3%，报5.57港元；来凯医药-B(02105)涨9.15%，报6.44港元；荣昌生物(09995)涨6.29%，报31.25港元；君实生物(01877)涨5.65%，报10.28港元。甬兴证券指出，2023年医保基金运行总体平稳，该行认为随着国家医保局建立覆盖申报、评审、测算、谈判等全流程的创新药支持机制，更多新药好药有望纳入医保，创新药研发相关企业有望受益。东海证券表示，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109550.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429608199","title":"恒瑞医药(600276)：业绩企稳 创新药收入持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429608199","media":"海通证券","top":-1,"share":"https://www.laohu8.com/m/news/2429608199?lang=zh_cn&edition=full","pubTime":"2024-04-23 20:24","pubTimestamp":1713875064,"startTime":"0","endTime":"0","summary":"收入增长稳健，创新药持续放量。销售费用率和研发费用率降低，带动利润增长快于收入。公司在毛利率维持84.55%的情况下，将销售费用率和研发费用率分别下降至33.20%、21.71%，带动利润快速增长。我们认为销售费用率下降主要系公司持续的销售改革、降本增效；研发费用率下降主要系公司整体研发投入略有下降。2023 年公司上市3 款1 类新药，获得14 项NDA 受理，进入I 期-III 期的管线项目数分别为30、35、12。截至年底，公司累计上市15 款1 类新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042320242687a61e15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042320242687a61e15&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429674191","title":"腾讯出手，投了家创新药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429674191","media":"猎云精选","top":-1,"share":"https://www.laohu8.com/m/news/2429674191?lang=zh_cn&edition=full","pubTime":"2024-04-23 20:10","pubTimestamp":1713874200,"startTime":"0","endTime":"0","summary":"腾讯又抛出了一笔投资。这不是腾讯首次加码创新药。2020年12月，腾讯独家投资了基因治疗公司和元生物，2022年3月，和元生物在科创板上市，截至目前，和元生物市值已超33亿元。2021年2月，腾讯完成了对华毅乐健的天使轮融资，华毅乐健同样是一家专注于基因治疗创新药开发的生物技术公司。2023年11月，腾讯投资宁丹新药，公司业务主要聚焦中枢神经系统疾病新药开发领域。腾讯AI Lab于2017年开始AI+医疗探索，于2019年初启动了药物研发项目。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/23201040372656.shtml","is_publish_highlight":false,"gpt_icon":1},{"id":"2429164192","title":"复星医药董秘回复： 张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官，复宏汉霖执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164192","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429164192?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:12","pubTimestamp":1713867125,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药(600196)04月23日在投资者关系平台上答复投资者关心的问题。投资者：请问张文杰在公司主要负责哪方面工作？复星医药董秘：投资者您好，感谢您对公司的关注。张文杰先生现任本公司执行总裁、创新药事业部联席首席执行官，复宏汉霖执行董事、董事会主席，以及合营公司复星凯特董事长。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231812078b4a279c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231812078b4a279c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164862","title":"京新药业：作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164862","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429164862?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:04","pubTimestamp":1713866676,"startTime":"0","endTime":"0","summary":"作为一款创新药，地达西尼具有特殊的新作用机制及其带来的疗效提升。公司除了化药地达西尼之外，中成药当中的滋肾宁神丸、润肠宁神膏和补血宁神片都具有安神的功效。地达西尼主要用于失眠患者的短期治疗。地达西尼由于其创新的作用机制，在临床试验阶段显现出包括长期服用戒断反应等方面的较好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035523.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429540831","title":"恒瑞医药(600276)2023年年报及2024年一季报点评：创新药驱动业绩增长，领军创新药行业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2429540831","media":"光大证券","top":-1,"share":"https://www.laohu8.com/m/news/2429540831?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:17","pubTimestamp":1713856648,"startTime":"0","endTime":"0","summary":"但仿制药收入略有下滑，第二批集采涉及产品注射用紫杉醇、醋酸阿比特龙片因多数省份集采续约未中标及降价等因素影响，2023年销售额同比减少7.02亿元，2022年11月开始执行的第七批集采涉及产品2023年销售额同比减少9.11亿元。2023年现金流状况大幅改善，主要系收入增长及客户回款加快，销售商品收到的现金增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231530218b498568&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231530218b498568&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429151380","title":"A股收评 | 创新药午后爆发 人形机器人走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2429151380","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429151380?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:12","pubTimestamp":1713856324,"startTime":"0","endTime":"0","summary":"4月23日，A股震荡分化，创业板指小幅收涨。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240423/20240423151211_41842.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240423/20240423151211_41842.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107429.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429153834","title":"港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2429153834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429153834?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:55","pubTimestamp":1713851752,"startTime":"0","endTime":"0","summary":"消息面上，近日，北京市医保局印发《北京市支持创新医药高质量发展若干措施》。东海证券近日研报指出，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。中长期来看，持续看好创新药、特色器械等代表新质生产力发展方向的投资机会；中短期来看，重点关注品牌中药、连锁药店、血制品等低估值、高股息，成长稳健的相关板块及个股的投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429306411","title":"创新药概念午后震荡回升 甘李药业涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2429306411","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2429306411?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:24","pubTimestamp":1713849840,"startTime":"0","endTime":"0","summary":" 4月23日消息，创新药概念午后震荡回升，甘李药业涨停股价创1月10日以来新高，凯因科技、奥赛康、亿帆医药、吉贝尔、荣昌生物等跟涨。本次接续采购全国共有35000多家医疗机构参加，填报胰岛素需求量超过2.4亿支，涵盖临床常用的二代和三代胰岛素。 据报道，根据现场企业签到表，此次续标涉及13家企业，包括诺和诺德、礼来、赛诺菲、甘李药业、东阳光药业、联邦制药、通化东宝等药企到场签到并递交材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/2024-04-23/doc-inasuzea8087575.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2024-04-23/doc-inasuzea8087575.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429362421","title":"联环药业钱振华：持续加大研发投入，加速推进创新药、高端仿制药等研发进度","url":"https://stock-news.laohu8.com/highlight/detail?id=2429362421","media":"地产k线","top":-1,"share":"https://www.laohu8.com/m/news/2429362421?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:12","pubTimestamp":1713841961,"startTime":"0","endTime":"0","summary":"瑞财经 吴文婷4月22日，联环药业发布2023年度业绩说明会。针对2023年净利润下滑，董事长、董事会秘书钱振华解释称，主要是因为研发投入较2022年大幅增加。据其指出，2024年，公司将不断加大研发投入，加速推进创新药、特色制剂、高端仿制药等品种的研发进度。联环药业所属行业为医药制造业，是集研发、生产、销售为一体的国家高新技术企业。据2023年年报显示，联环药业实现营业收入约21.74亿元，同比增长11.2%；归属于上市公司股东的净利润约1.35亿元，同比减少4.5%。相关公司：联环药业sh600513","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231114298b488907&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231114298b488907&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429794217","title":"天士力获首创证券买入评级，业绩符合预期，中药创新药有望进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2429794217","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429794217?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:03","pubTimestamp":1713783820,"startTime":"0","endTime":"0","summary":"4月22日，天士力获首创证券买入评级，近一个月天士力获得6份研报关注。研报预计2024年至2026年公司营业收入分别为91.40亿元、97.30亿元和103.54亿元，同比增速分别为5.4%、6.5%和6.4%；归母 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240422/c657147625.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429666948","title":"恒瑞医药(600276)2023年年报及2024年一季报点评：创新药快速增长，研发管线亮点纷呈","url":"https://stock-news.laohu8.com/highlight/detail?id=2429666948","media":"兴业证券","top":-1,"share":"https://www.laohu8.com/m/news/2429666948?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:17","pubTimestamp":1713777470,"startTime":"0","endTime":"0","summary":"投资要点公司发布2023年年报及2024年一季报。创新药快速增长。在研管线亮点纷呈。2023年公司销售、研发、管理费用率分别为33.20%、10.59%、21.71%，同比分别降低1.34pp、1.26pp、0.25pp。考虑到对外许可收入确认对2024年业绩的增厚，我们调整盈利预测，预计2024-2026年公司EPS分别为0.93、1.08、1.25元，2024年4月19日收盘价对应的2024-2026年市盈率分别为44.9、38.7、33.4倍，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221731078b45964c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221731078b45964c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429297916","title":"恒瑞医药(600276)年报点评：创新药驱动收入增长，2024年迎来产品上市高峰","url":"https://stock-news.laohu8.com/highlight/detail?id=2429297916","media":"国联证券","top":-1,"share":"https://www.laohu8.com/m/news/2429297916?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:14","pubTimestamp":1713770091,"startTime":"0","endTime":"0","summary":"事件：恒瑞医药 公布2023年年报和2024年一季报。看好恒瑞医药的肿瘤和慢病的丰富研发储备2023年公司研发费用接近50亿元，截至2023年底恒瑞医药进入到NDA阶段的项目有14项，镇痛药物泰吉利定已于2024年上市，其他新产品包括PCSK9单抗、IL-17A单抗、JAK1抑制剂、2款滴眼液等有望于年内上市。恒瑞医药在乳腺癌、肺癌、肝癌的药物开发逐步形成矩阵式布局，非肿瘤疾病中自免、降糖、肾病用途药物布局丰富。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221529548b44f05f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221529548b44f05f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428251730","title":"中国生物制药(01177.HK)创新药罗伐昔替尼片关键注册研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2428251730","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428251730?lang=zh_cn&edition=full","pubTime":"2024-04-19 01:08","pubTimestamp":1713460080,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib(TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团将于近期递交TQ05105片的上市申请。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-18 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343409/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2426445192","title":"中国生物制药(01177.HK)三款创新药在AACR公布六项研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2426445192","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426445192?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:53","pubTimestamp":1712771580,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团开发的三款创新药“盐酸安罗替尼胶囊”、“TQB2916(CD40激动剂)”、“FHND6091(蛋白酶体抑制剂)”已在2024年美国癌症协会年会(AACR)公布6项研究成果。研究表明，安罗替尼(消化道肿瘤)联合化疗一线治疗伴不可切除肝转移消化道肿瘤，尤其是胰腺癌，响应良好，有望为患者提供一种新的治疗策略。TQB2916能够与CD40结合，增加细胞因子释放，激活免疫，起到抗肿瘤作用。FHND6091的药理属性得到了全面验证。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-10 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341413/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0636},{"period":"3month","weight":-0.093},{"period":"6month","weight":-0.2237},{"period":"1year","weight":-0.2609},{"period":"ytd","weight":-0.1964}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.009},{"period":"1year","weight":-0.0674},{"period":"ytd","weight":0.0235}],"serverTime":1714042474748,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}